BACKGROUND:Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. METHODS: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). RESULTS:RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. CONCLUSIONS: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
RCT Entities:
BACKGROUND: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. METHODS: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). RESULTS:RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. CONCLUSIONS: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
Authors: Yves Dauvilliers; Carlos H Schenck; Ronald B Postuma; Alex Iranzo; Pierre-Herve Luppi; Giuseppe Plazzi; Jacques Montplaisir; Bradley Boeve Journal: Nat Rev Dis Primers Date: 2018-08-30 Impact factor: 52.329